Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Present and Future of Artificial Intelligence in Pathology.
Usta U, Taştekin E. Usta U, et al. Among authors: tastekin e. Balkan Med J. 2024 May 3;41(3):157-158. doi: 10.4274/balkanmedj.galenos.2024.2024.060324. Balkan Med J. 2024. PMID: 38700263 Free PMC article. No abstract available.
Correlation between pre-radical prostatectomy standardized SUVmax ratios detected on 68Ga-PSMA-I&T PET/CT and final histopathology outcomes: an in-depth analysis.
Arıkan MG, Soyluoğlu S, Korkmaz Ü, Taştekin E, Elboğa U, Arda E. Arıkan MG, et al. Among authors: tastekin e. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024 Mar-Apr;43(2):100-106. doi: 10.1016/j.remnie.2024.02.002. Epub 2024 Feb 6. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024. PMID: 38331250
A Comprehensive Approach to the Thyroid Bethesda Category III (AUS) in the Transition Zone Between 2nd Edition and 3rd Edition of The Bethesda System for Reporting Thyroid Cytopathology: Subcategorization, Nuclear Scoring, and More.
Bagıs M, Can N, Sut N, Tastekin E, Erdogan EG, Bulbul BY, Sezer YA, Kula O, Demirtas EM, Usta I. Bagıs M, et al. Among authors: tastekin e. Endocr Pathol. 2024 Mar;35(1):51-76. doi: 10.1007/s12022-024-09797-1. Epub 2024 Jan 27. Endocr Pathol. 2024. PMID: 38280141 Free PMC article.
Conventional Tools for Predicting Satisfactory Response to Neoadjuvant Chemotherapy in HR+/HER2- Breast Cancer Patients.
Oprea AL, Gulluoglu B, Aytin YE, Eren OC, Aral C, Szekely TB, Tastekin E, Kaya H, Bademler S, Karanlik H, Sezer A, Ugurlu MU, Turdean SG, Georgescu R, Marginean C. Oprea AL, et al. Among authors: tastekin e. Breast Care (Basel). 2023 Oct;18(5):344-353. doi: 10.1159/000531117. Epub 2023 May 20. Breast Care (Basel). 2023. PMID: 37901046
85 results